News Release 

Tocilizumab vs standard care on preventing worsening in patients hospitalized with COVID-19 pneumonia

JAMA Internal Medicine

Research News

What The Study Did: Researchers in this randomized clinical trial compared the effect of early administration of tocilizumab with standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia.

Authors: Carlo Salvarani, M.D., of Unita Operativa di Reumatologia in Reggio Emilia, Italy, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamainternmed.2020.6615)

Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

###

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.6615?guestAccessKey=05e037ab-d891-4213-b298-6b97f63fd8f7&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102020

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.